Abstract :

Xenotransplantation is an approach which will be able to support the increasing demand of organ donation since the organ does not need to come from humans. Up till now, xenotransplantation is still barely performed since its risk and chance of success are still not proven to be safe. One of the biggest obstacles is rejection which may lead to xenograft failure and can occur in certain types and from certain causes. However, the risk of rejection can be minimized by the process of genetic engineering and applying anti-rejection drugs in which scientists and researchers are developing so that the procedure becomes safer in the future. Although the patient who was considered as the first successful xenotransplantation in human case had died a few months after the surgery and the cause of death still remains unsolved, the field of xenotransplantation still keeps developing by researchers, medical universities, and biotechnology companies since they all agree that xenotransplantation will produce lots of advantages and will be a big step of the medical treatment field. Despite the fact that xenotransplantation is a procedure that is risky and raises public concerns and ethical issues, the procedure is still believed to give more benefits towards the patient and medical development since serious problems like organ shortage and high number of deaths on the waiting list will be solved.

---

Keywords :

Cardiac xenotransplantation; PERV; Xenotransplantation.

---

References :

1. A. Qualls, G. D. Lewis, V. Sanchorawala, and A. Staron, “Orthotopic heart transplant rejection in association with immunomodulatory therapy for AL amyloidosis: a case series and review of the literature,” American Journal of Transplantation, vol. 19, no. 11, pp. 3185-3190, 2019.
2. N. Pierson Iii et al., “Progress toward cardiac xenotransplantation,” Circulation, vol. 142, no. 14, pp. 1389-1398, 2020.
3. S. Raza, H. Hara, D. C. Cleveland, and D. K. C. Cooper, “The potential of genetically engineered pig heart transplantation in infants with complex congenital heart disease,” Pediatric Transplantation, p. e14260, 2022.
4. K. C. Cooper and R. N. Pierson, “The future of cardiac xenotransplantation,” Nature Reviews Cardiology, pp. 1-2, 2022.
5. Längin et al., “Consistent success in life-supporting porcine cardiac xenotransplantation,” Nature, vol. 564, no. 7736, pp. 430-433, 2018.
6. B. Egerer, “Provision of safe donor pigs for xenotransplantation,” 2020.
7. P. Thompson et al., “A perspective on the potential detrimental role of inflammation in pig orthotopic heart xenotransplantation,” Xenotransplantation, vol. 28, no. 4, p. e12687, 2021.
8. K. C. Cooper, “A Brief History of Clinical Cross-Species Organ Xenotransplantation,” in Clinical Xenotransplantation: Springer, 2020, pp. 3-26.
9. Perico, F. Casiraghi, and G. Remuzzi, “Clinical Kidney Xenotransplantation: Major Progress but More Work Needs to Be Done,” Nephron, pp. 1-6, 2022.
10. Shu, J. Ren, and J. Song, “Cardiac xenotransplantation: a promising way to treat advanced heart failure,” Heart Failure Reviews, vol. 27, no. 1, pp. 71-91, 2022.
11. Burdorf, A. M. Azimzadeh, and R. N. Pierson Iii, “Progress and challenges in lung xenotransplantation: an update,” Current Opinion in Organ Transplantation, vol. 23, no. 6, pp. 621-627, 2018.
12. Q. Yang, A. C. Park, and J. D. Schilling, “Cardiac Xenotransplantation: Five things every cardiologist should know,” ed: American College of Cardiology Foundation Washington DC, 2022.
13. P. H. Meier et al., “Xenotransplantation: back to the future?,” Transplant international, vol. 31, no. 5, pp. 465-477, 2018.
14. Narayan, R. Verma, and I. Ali, “XENOTRANSPLANTATION–A REVIEW,” 2018.
15. Barone et al., “Glycosphingolipids of porcine, bovine, and equine pericardia as potential immune targets in bioprosthetic heart valve grafts,” Xenotransplantation, vol. 25, no. 5, p. e12406, 2018.
16. J. Tector, M. Mosser, M. Tector, and J.-M. Bach, “The possible role of anti-Neu5Gc as an obstacle in xenotransplantation,” Frontiers in immunology, vol. 11, p. 622, 2020.
17. Naeimi Kararoudi et al., “Clustered regularly interspaced short palindromic repeats/Cas9 gene editing technique in xenotransplantation,” Frontiers in immunology, p. 1711, 2018.
18. M. Thurman, S. E. Panzer, and M. Le Quintrec, “The role of complement in antibody mediated transplant rejection,” Molecular immunology, vol. 112, pp. 240-246, 2019.
19. K. C. Cooper, M. Ezzelarab, H. Iwase, and H. Hara, “Perspectives on the optimal genetically-engineered pig in 2018 for initial clinical trials of kidney or heart xenotransplantation,” Transplantation, vol. 102, no. 12, p. 1974, 2018.
20. E. Goerlich, J. L. Chan, and M. M. Mohiuddin, “Regulatory barriers to xenotransplantation,” Current Opinion in Organ Transplantation, vol. 24, no. 5, pp. 522-526, 2019.
21. Jorqui-Azofra, “Regulation of Clinical Xenotransplantation: A Reappraisal of the Legal, Ethical, and Social Aspects Involved,” Xenotransplantation, pp. 315-358, 2020.
22. Haddow, “‘Dirty pigs’ and the xenotransplantation paradox,” Medical Humanities, vol. 47, no. 4, pp. 417-424, 2021.
23. P. H. Meier et al., “Recent progress and remaining hurdles toward clinical xenotransplantation,” Xenotransplantation, vol. 28, no. 3, p. e12681, 2021.
24. Niu et al., “Porcine genome engineering for xenotransplantation,” Advanced Drug Delivery Reviews, vol. 168, pp. 229-245, 2021.
25. Hryhorowicz, D. Lipiński, S. Hryhorowicz, A. Nowak-Terpiłowska, N. Ryczek, and J. Zeyland, “Application of genetically engineered pigs in biomedical research,” Genes, vol. 11, no. 6, p. 670, 2020.
26. Zhai et al., “Epigenetic states of donor cells significantly affect the development of somatic cell nuclear transfer (SCNT) embryos in pigs,” Molecular Reproduction and Development, vol. 85, no. 1, pp. 26-37, 2018.
27. Wiater et al., “The effect of recombinant human alpha-1, 2-fucosyltransferase and alpha-galactosidase A on the reduction of alpha-gal expression in the liver of transgenic pigs,” Folia Biologica (Kraków), vol. 68, no. 4, pp. 121-133, 2020.
28. W. Matson, N. Hosny, Z. A. Swanson, B. J. Hering, and C. Burlak, “Optimizing sgRNA length to improve target specificity and efficiency for the GGTA1 gene using the CRISPR/Cas9 gene editing system,” PloS one, vol. 14, no. 12, p. e0226107, 2019.
29. Byrne, S. Ahmad‐Villiers, Z. Du, and C. McGregor, “B4GALNT2 and xenotransplantation: a newly appreciated xenogeneic antigen,” Xenotransplantation, vol. 25, no. 5, p. e12394, 2018.
30. Tritschler et al., “New Insights into Xenotransplantation for Cartilage Repair: Porcine Multi-Genetically Modified Chondrocytes as a Promising Cell Source,” Cells, vol. 10, no. 8, p. 2152, 2021.
31. A. Kim et al., “Generation by somatic cell nuclear transfer of GGTA1 knockout pigs expressing soluble human TNFRI-Fc and human HO-1,” Transgenic Research, vol. 28, no. 1, pp. 91-102, 2019.
32. E. Buchwald and P. N. Martins, “Designer organs: The future of personalized transplantation,” Artificial Organs, vol. 46, no. 2, pp. 180-190, 2022.
33. Brenner et al., “Study for Comparison of CD40-mAb and CD40L-Ab Costimulation Blockade after Life-Supporting Orthotopic Cardiac Xenotransplantation of Multi-Transgenic Pig Hearts into Baboons with a Worldwide First Successful Long-Term Survival,” Transplantation, vol. 102, p. S312, 2018.
34. Wang, W. He, Y. Ruan, and Q. Geng, “First pig-to-human heart transplantation,” The Innovation, vol. 3, no. 2, p. 100223, 2022.
35. J. Hawthorne et al., “Third WHO global consultation on regulatory requirements for xenotransplantation clinical trials, Changsha, hunan, China december 12-14, 2018:” the 2018 Changsha communique” the 10-year anniversary of the international consultation on xenotransplantation,” Xenotransplantation, vol. 26, no. 2, p. e12513, 2019.
36. Watanabe et al., “Intra‐bone bone marrow transplantation from hCD47 transgenic pigs to baboons prolongs chimerism to> 60 days and promotes increased porcine lung transplant survival,” Xenotransplantation, vol. 27, no. 1, p. e12552, 2020.
37. M. Porrett et al., “First clinical‐grade porcine kidney xenotransplant using a human decedent model,” American Journal of Transplantation, 2022.
38. M. Ladowski et al., “Swine leukocyte antigen (SLA) class II is a xenoantigen,” Transplantation, vol. 102, no. 2, p. 249, 2018.
39. Brenner et al., “Worldwide first successful long-term survival after orthotopic cardiac xenotransplantation of multitransgenic pig hearts into baboons using a CD40mAb or CD40L Costimulation blockade,” The Thoracic and Cardiovascular Surgeon, vol. 66, no. S 01, pp. DGTHG-V271, 2018.
40. N. Pierson Iii, L. Burdorf, J. C. Madsen, G. D. Lewis, and D. A. D’Alessandro, “Pig‐to‐human heart transplantation: who goes first?,” American Journal of Transplantation, vol. 20, no. 10, pp. 2669-2674, 2020.
41. Stevens, “Genome engineering for xenotransplantation,” Genet. Eng. Glimpse Tech. Appl, 2019.
42. Iwase et al., “Indicators of impending pig kidney and heart xenograft failure: Relevance to clinical organ xenotransplantation-Review article,” International Journal of Surgery, vol. 70, pp. 84-91, 2019.
43. R. Garcia et al., “Clinical trials in cardiac xenotransplantation: Are we ready to overcome barriers?,” Journal of Cardiac Surgery, vol. 36, no. 10, pp. 3796-3801, 2021.
44. D. Loike and A. Kadish, “Ethical rejections of xenotransplantation? The potential and challenges of using human‐pig chimeras to create organs for transplantation,” EMBO reports, vol. 19, no. 8, p. e46337, 2018.
45. J. Hawthorne and P. J. Cowan, “Xenotransplantation in Australia: development of the regulatory process,” Xenotransplantation, vol. 27, no. 3, p. e12603, 2020.
46. M. DeFilippis, K. K. Khush, M. A. Farr, A. Fiedler, A. Kilic, and M. M. Givertz, “Evolving characteristics of heart transplantation donors and recipients: JACC focus seminar,” Journal of the American College of Cardiology, vol. 79, no. 11, pp. 1108-1123, 2022.
47. Cozzi et al., “Organ transplants of the future: planning for innovations including xenotransplantation,” Transplant International, vol. 34, no. 11, pp. 2006-2018, 2021.
48. A. Fishman, D. H. Sachs, K. Yamada, and R. A. Wilkinson, “Absence of interaction between porcine endogenous retrovirus and porcine cytomegalovirus in pig‐to‐baboon renal xenotransplantation in vivo,” Xenotransplantation, vol. 25, no. 5, p. e12395, 2018.
49. Bikhet et al., “The immune system in infants: Relevance to xenotransplantation,” Pediatric transplantation, vol. 24, no. 7, p. e13795, 2020.